Variables | OS | PFS | LC | |||||||
---|---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | ||
Age, years | < 65 | 1/reference | 1 | 1 | ||||||
≥ 65 | 4.655 | 1.389–15.59 | 0.003 | 2.618 | 0.992–6.906 | 0.033 | 3.1035 | 1.067–9.028 | 0.019 | |
Gender | Female | 1 | 1 | 1 | ||||||
Male | 2.021 | 0.906–4.505 | 0.076 | 1.312 | 0.630–2.733 | 0.466 | 1.324 | 0.618–2.833 | 0.468 | |
ECOG PS | 0 | 1 | 1 | 1 | ||||||
> 1 | 2.555 | 1.168–5.589 | 0.024 | 2.013 | 0.925–4.382 | 0.091 | 1.893 | 0.8399–4.265 | 0.139 | |
Clinical stage | ≤ stage 3 | 1 | 1 | 1 | ||||||
> stage 4 | 2.583 | 0.874–7.632 | 0.058 | 2.905 | 0.994–8.490 | 0.029 | 3.715 | 1.099–12.56 | 0.014 | |
T category | ≤ T3 | 1 | 1 | 1 | ||||||
> T3 | 1.204 | 0.548–2.649 | 0.642 | 2.316 | 0.984–5.453 | 0.041 | 2.567 | 1.0298–6.399 | 0.029 | |
N category | ≤ N2b | 1 | 1 | 1 | ||||||
> N2b | 2.794 | 1.077–7.252 | 0.052 | 4.117 | 1.722–9.845 | 0.004 | 4.430 | 1.831–10.72 | 0.003 | |
Location | Lower | 1 | 1 | 1 | ||||||
Upper | 0.909 | 0.423–1.950 | 0.806 | 0.796 | 0.382–1.658 | 0.542 | 0.7923 | 0.370–1.695 | 0.548 | |
Chemotherapy | IACRT | 1 | 1 | 1 | ||||||
SCRT | 2.34 | 1.012–5.41 | 0.047 | 2.334 | 1.058–5.149 | 0.048 | 2.586 | 1.156–5.786 | 0.030 | |
RT field | primary tumor | 1 | 1 | 1 | ||||||
cervical LN area | 0.727 | 0.171–3.098 | 0.680 | 1.492 | 0.348–6.390 | 0.6099 | 1.591 | 0.369–6.858 | 0.558 | |
Prescribed total dose | ≤60 Gy | 1 | 1 | 1 | ||||||
> 60 Gy | 1.003 | 0.438–2.299 | 0.993 | 2.225 | 1.066–4.65 | 0.0378 | 2.177 | 1.015–4.672 | 0.0515 |